arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Biofrontera Inc.

BFRI
$1.26 ▲ +0.01 (+0.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
7 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Biofrontera Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $12.8M
Dividend Yield
Revenue Growth 11.7%
Op. Margin -27.2%
ROIC -108.5%
FCF / Share $-1.31
Trailing P/E
Price / Book 1.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$41.70M
↑ +11.7%
Net Income Profit after all expenses
$-10.54M
↑ +40.7%
Operating Margin Operating profit as % of sales
-27.2%
↑ +41.0% 8th
FCF / Share Free cash flow per share
$-1.31
↑ +29.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
8
Returns
9
Financial Health
3
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 25 quarters